Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer

Table 3 Characteristics of patients with response to nivolumab

Age	PS	Genomic alteration			PD-L1+ in TC	CPS≥10	CPS≥1	EBV	MMR
Age	PS	Mutation	Amplification	TMB/Mb	PD-L1+ in TC	CPS≥10	CPS≥1	EBV	MMR
63	0	NE	NE	NE	–	+	+	–	MMR-D
63	0	NE	NE	NE	+	+	+	–	MMR-D
66	0	PIK3CA, TP53	None	38.3	+	–	+	–	MMR-D
62	0	PIK3CA	None	11.5	–	–	+	–	MMR-D
53	1	None	None	7.7	+	+	+	–	MMR-D
79	0	MET, PIK3CA, TP53	None	58.0	+	–	+	–	MMR-D
64	0	PIK3CA	None	15.3	+	+	+	–	MMR-P
74	0	ARID1A, TP53	CCNE1	15.1	–	–	+	–	MMR-P
80	0	TP53	CCNE1	11.5	–	–	+	–	MMR-P
76	0	None	None	10.1	–	–	+	–	MMR-P
73	0	TP53	None	5.0	+	+	+	–	MMR-P
65	0	NE	NE	NE	+	+	+	–	MMR-P
53	0	NE	NE	NE	+	–	+	–	MMR-P
43	0	TP53	None	7.7	–	–	+	+	MMR-P

CPS combined positive score, EBV Epstein-Barr virus, MMR mismatch repair, MMR-D mismatch repair deficient, MMR-P mismatch repair proficient, NE not examined, ORR objective response rate, PD-L1 programmed cell death-1 ligand-1, PS Eastern Cooperative Oncology Group performance status, TMB tumor mutation burden